Altamira Therapeutics

1. Executive Summary (Confidence: High)

Altamira Therapeutics is currently undergoing a radical strategic repositioning, shifting its focus from legacy clinical development in inner ear and allergic rhinitis to becoming a "leading provider of innovative RNA delivery technology". The organization’s value proposition is built upon its proprietary "xPhore" platform (encompassing OligoPhore and SemaPhore), which utilizes a patented peptide to deliver siRNA and mRNA to extrahepatic tissues—a major bottleneck in the RNA industry. Despite a turbulent 2024–2025 marked by a transition from Nasdaq to the OTCQB marketplace and a critically low cash position (reporting only $4,000 as of June 2025), Altamira continues to advance its flagship AM-401 program toward an IND submission. Its "picks and shovels" strategy involves out-licensing its platform to biopharma partners and spinning off its RNA delivery business into a separate subsidiary (ATAG) to attract private equity funding.